HBsAg Hijacking of TBK1: Mechanistic Insights into Immune Evasion and Autophagy in HBV Infection

Study Background and Research Question

Chronic hepatitis B virus (HBV) infection remains a major global health concern, with approximately 350 million individuals at risk for liver cancer due to persistent viral replication. The viral surface antigen, HBsAg, is central to HBV's life cycle—facilitating entry, assembly, and secretion of viral particles. Despite detailed knowledge of HBV structure and innate immune recognition pathways, the molecular crosstalk between HBsAg, host innate immunity, and autophagy has not been fully elucidated. The reference study (Luo et al., 2025) addresses this gap by investigating how HBsAg modulates the TANK-binding kinase 1 (TBK1) pathway to suppress type I interferon (IFN-I) responses and trigger autophagy, potentially contributing to HBV persistence.

Key Innovation from the Reference Study

The primary innovation of this work lies in uncovering a direct mechanism by which HBsAg manipulates host cell signaling to subvert antiviral defenses. The study demonstrates that HBsAg physically interacts with the kinase domain of TBK1, promoting TBK1 dimerization. This interaction disrupts the canonical TBK1–IRF3 signaling axis, thereby suppressing IFN-I production. Simultaneously, HBsAg-induced TBK1 activation enhances phosphorylation of sequestosome-1 (p62), a pivotal autophagy receptor, promoting the accumulation of autophagosomes. Notably, HBsAg also impedes the fusion of autophagosomes with lysosomes by downregulating SNAP29, resulting in incomplete autophagic flux. These dual actions—immune suppression and autophagy modulation—provide a molecular explanation for how HBV achieves immune evasion and persistence (Luo et al., 2025).

Methods and Experimental Design Insights

The study employs a combination of in vitro and in vivo approaches to dissect the interplay between HBsAg and TBK1. Key methodologies include:

• Cellular Models: Hepatocyte cultures expressing HBsAg and control constructs.
• Animal Models: Transgenic mice expressing HBsAg and liver biopsies from chronic HBV patients.
• Phosphorylation Assays: Western blotting and immunoprecipitation to monitor TBK1, IRF3, and p62 phosphorylation states.
• Protein Interaction Mapping: Co-immunoprecipitation and mutational analyses to define HBsAg–TBK1 binding interfaces.
• Reporter Assays: Luciferase-based readouts for IFNβ promoter activity.
• Autophagy Assays: Quantification of autophagosome accumulation, LC3-II/I conversion, and p62 dynamics.
• Pharmacological Inhibition: Use of BX795, a TBK1 inhibitor, to dissect pathway dependencies.

These approaches collectively establish causality between HBsAg expression, TBK1 pathway modulation, and downstream effects on both interferon production and autophagic flux.

Core Findings and Why They Matter

The study's findings reveal a sophisticated viral strategy:

• Suppression of IFN-I: HBsAg augments TBK1 dimerization but sequesters TBK1 away from IRF3, resulting in decreased IRF3 phosphorylation and impaired IFN-I signaling. This effect was validated both in cultured hepatocytes and in liver tissue from HBsAg transgenic mice and chronic HBV patients.
• Induction of Early Autophagy: HBsAg-activated TBK1 increases p62 phosphorylation and autophagosome formation. However, by repressing SNAP29 expression, HBsAg blocks autophagosome–lysosome fusion, leading to incomplete autophagy and accumulation of p62-positive compartments.
• Functional Consequences: These dual actions promote HBV replication and persistence by both evading innate immune clearance and exploiting autophagic machinery (Luo et al., 2025).

This mechanistic insight advances our understanding of HBV pathogenesis and highlights the dual role of autophagy as both a host defense and a viral subversion tool.

Comparison with Existing Internal Articles

Previous discussions on the convergence of autophagy modulation and innate immunity, such as in "Strategic Modulation of Autophagy and Innate Immunity", have emphasized the relevance of autophagy modulators—including Chloroquine Diphosphate—as tools for dissecting the interplay between TLR7/TLR9 signaling, G1 phase cell cycle arrest, and interferon responses in cancer and infectious disease models. The current reference study provides direct evidence that viral proteins like HBsAg manipulate this axis by targeting TBK1, thereby bridging prior theoretical frameworks with experimentally validated mechanisms.

Furthermore, internal resources such as "Chloroquine Diphosphate (SKU A8628): Data-Driven Solution..." and "Chloroquine Diphosphate: Autophagy Modulator for Cancer R..." have documented the utility of Chloroquine diphosphate as an autophagy assay reagent and as a sensitizer in cancer research, with mechanistic overlap in inhibiting autophagosome–lysosome fusion—echoing the incomplete autophagy observed with HBsAg. These relationships support the translational relevance of the paper's mechanistic findings for both infectious disease and cancer research contexts.

Limitations and Transferability

Despite its robust mechanistic findings, the study has several limitations. Most mechanistic work is performed in hepatocyte lines and murine models, which may not fully recapitulate human pathophysiology. The study focuses on HBsAg and does not address how other HBV proteins may interact with autophagy or innate immunity pathways. Additionally, while the disruption of autophagic flux is well characterized, the downstream consequences for antigen presentation and immune cell recruitment remain to be investigated. Transferability to non-hepatic models or other viral systems should be approached cautiously until further validation is available.

Protocol Parameters

• Autophagy assay design: Use LC3-II/I and p62 as readouts to assess autophagosome accumulation and flux in response to HBsAg or pharmacological modulators.
• TBK1 inhibition: BX795 is effective for pathway dissection; typical concentrations range from 1–5 μM in cell culture, but titration is recommended for each model.
• Chloroquine diphosphate application: For blocking autophagosome–lysosome fusion, in vitro IC50 values for chloroquine diphosphate are typically 15–40 μM, depending on cell type (see product information).
• Gene expression analysis: Use qPCR and reporter assays to monitor IFNβ, ISG15, and ISG56 in response to HBsAg or pathway modulators.
• Animal studies: HBsAg transgenic mice or hydrodynamic injection models provide relevant in vivo platforms for immune and autophagy phenotyping.

Why this cross-domain matters, maturity, and limitations

The intersection between autophagy modulation and innate immunity, as highlighted in both HBV infection and cancer research, underscores the utility of shared mechanistic tools and readouts across domains. Chloroquine diphosphate, for example, is widely used to dissect autophagic flux in both virology and oncology. However, while translational overlap exists, each domain has unique context-dependent variables—such as immune cell composition and tissue microenvironment—that may influence outcomes. Maturity of cross-application is highest at the mechanistic assay level, but extrapolation to therapeutic strategies requires careful validation in disease-specific models.

Outlook

This work provides compelling evidence that viral antigens can co-opt host kinases to subvert immune defense and remodel autophagy, offering new molecular targets for antiviral intervention. The mechanistic parallels with cancer cell autophagy modulation suggest opportunities for cross-disciplinary research, particularly for those designing autophagy assays or exploring innate immunity crosstalk. Future directions should include exploring the downstream impact of incomplete autophagy on antigen presentation, immune cell activation, and long-term viral persistence, leveraging both established and emerging autophagy modulators.

Research Support Resources

To facilitate similar mechanistic studies, researchers can employ Chloroquine diphosphate (SKU A8628, 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine;phosphoric acid) as a validated tool to block autophagosome–lysosome fusion in autophagy assays, as supported by both the reference study and internal resources. The high aqueous solubility and well-characterized IC50 range (15–40 μM in vitro) make it suitable for dissecting autophagy-dependent mechanisms in both infection and cancer models. For detailed protocols and additional workflow recommendations, see APExBIO's product page and the internal article "Chloroquine Diphosphate: Autophagy Modulator for Cancer Research".